Pedro Exman(@PedroExman) 's Twitter Profileg
Pedro Exman

@PedroExman

👨‍⚕️Oncologista no @hospitalalemao-especializado em câncer de mama,👨‍👩‍👦‍👦pai do Alê, Gui e do Lipe, marido da Monique. ⚽️Corinthians e 🏈Patriots

ID:897604243137454081

linkhttp://www.pedroexman.com calendar_today15-08-2017 23:41:43

325 Tweets

311 Followers

338 Following

Dr Sarah Sammons(@drsarahsam) 's Twitter Profile Photo

40% of premenopausal pts discontinued ovarian suppression (OS)/AI early.

In deciding b/w chemo and OS/AI, it is pivotable to consider this fact. As we use less chemo, leaning on OS, we need tools to ID those at risk on non-adherence + how to intervene.

acsjournals.onlinelibrary.wiley.com/doi/epdf/10.10…

account_circle
Julie Gralow(@jrgralow) 's Twitter Profile Photo

Read and/or watch Eric Winer’s fantastic ⁦ASCO⁩ presidential address at - Partnering with Patients: The Cornerstone of Cancer Care and Research connection.asco.org/magazine/featu…

account_circle
Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO(@tomleblancMD) 's Twitter Profile Photo

This was by far one of the most powerful, touching, vulnerable, and inspiring moments of . A must read/watch for all! What remarkable leadership! ASCO has been so fortunate to have Eric Winer, MD at the helm this past year, and continuing in leadership roles thereafter

account_circle
Nancy Lin, MD(@nlinmd) 's Twitter Profile Photo

For those coming from the podcast, here is a link to the full article: Impact of Prior Authorization on Patient Access to Cancer Care | ASCO Educational Book ⁦Dario Trapani⁩ ⁦Nathan A. Pennell MD, PhD, FASCO⁩ ⁦Hope Rugo⁩ ⁦Lianne Kraemer⁩ ascopubs.org/doi/10.1200/ED…

account_circle
Pedro Exman(@PedroExman) 's Twitter Profile Photo

End of . Always the question: What will change tomorrow?
My answer :

ADAURA? I’d love but yet no wide access
NATALEE? Good, but abema data still more robust
SONIA? Amazing, but would be the same if others 2ndL or CDKs?

My champion🤩👇🏼
GREAT impact to pts NOW @oncoalert

End of #ASCO23. Always the question: What will change tomorrow? My answer : ADAURA? I’d love but yet no wide access NATALEE? Good, but abema data still more robust SONIA? Amazing, but would be the same if others 2ndL or CDKs? My champion🤩👇🏼 GREAT impact to pts NOW @oncoalert
account_circle
SEOM(@_SEOM) 's Twitter Profile Photo

🏙️ Desde Chicago, en ASCO
⭕️ Vídeo con highlights en cáncer de mama en onconexion.es
🗣️ Portavoz SEOM: Dra. Sonia Pernas, jefa de la Unidad de Cáncer de Mama del Institut Català d'Oncologia
👇🏻 Opinión personal

account_circle
Nancy Lin, MD(@nlinmd) 's Twitter Profile Photo

The STOP-HER2 study is now open and enrolling! Eligible patients are those with her2+ mbc who have been stable on first line systemic therapy at least 3 years. Translational Breast Cancer Research Consortium Heather Parsons

account_circle
Pedro Exman(@PedroExman) 's Twitter Profile Photo

The beauty of is when among incredible trials with new drugs and treatments, the most game-changing intervention in oncologists practice so far is the internalization of the Lynn M. Schuchter, MD, FASCO speech-the wonderful Eric Winer Eric Winer, MD

Lessons for life 🤩😌🥲
OncoAlert

The beauty of #ASCO23 is when among incredible trials with new drugs and treatments, the most game-changing intervention in oncologists practice so far is the internalization of the @ASCOPres speech-the wonderful Eric Winer @DrEricWiner Lessons for life 🤩😌🥲 @OncoAlert #bcsm
account_circle
Dana-Farber’s Breast Oncology Center(@DFCI_BreastOnc) 's Twitter Profile Photo

Congratulations to Jose Pablo Leone, MD who received a 2023 Conquer Cancer, the ASCO Foundation Advanced Clinical Research Award (ACRA) for Diversity and Inclusion! The award aims to increase diversity in the oncology workforce and research.
Read more here: ms.spr.ly/6013gbcxd

Congratulations to Jose Pablo Leone, MD who received a 2023 @ConquerCancerFd Advanced Clinical Research Award (ACRA) for Diversity and Inclusion! The award aims to increase diversity in the oncology workforce and #breastcancer research. Read more here: ms.spr.ly/6013gbcxd
account_circle
Ann Partridge MD, MPH(@AnnPartridgeMD) 's Twitter Profile Photo

Lynn M. Schuchter, MD, FASCO⁩ delivers outstanding presidential address ⁦@ASCO⁩ with so many messages re healthcare and life, especially the role of gratitude and support in our lives

⁦@ASCOPres⁩ delivers outstanding presidential address ⁦@ASCO⁩ with so many messages re healthcare and life, especially the role of gratitude and support in our lives #asco2023
account_circle
Pedro Exman(@PedroExman) 's Twitter Profile Photo

👨‍⚕️ We always want the best ttx for the pts and that’s why we are happy with + data
🤩 NATALEE is + ! Congrats to the authors👏
🤔But, pls correct me if this is wrong, the NNT is 52. we have to treat 52 pts for 3y to avoid 1 event?

Hard thoughts 😖 OncoAlert

👨‍⚕️ We always want the best ttx for the pts and that’s why we are happy with + data 🤩 NATALEE is + ! Congrats to the authors👏 🤔But, pls correct me if this is wrong, the NNT is 52. we have to treat 52 pts for 3y to avoid 1 event? Hard thoughts 😖 @OncoAlert #bcsm #ASCO23
account_circle
Pedro Exman(@PedroExman) 's Twitter Profile Photo

Not too much, not too little. Very interesting and insightful discussion by Dr. Ines Vaz Luis

💡 Young patients with agressive biologic ER+ disease have very concerning prognosis and may receive more intense endocrine-therapy.

OncoAlert

Not too much, not too little. Very interesting and insightful discussion by Dr. @ines_vazluis 💡 Young patients with agressive biologic ER+ disease have very concerning prognosis and may receive more intense endocrine-therapy. #bcsm @OncoAlert
account_circle